Written and maintained by CASRAI Editorial Board
Last updated
The FDA Breakthrough Device Designation—established under Section 515B of the Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 U.S.C. § 360e-3) as enacted by the 21st Century Cures Act of 2016—is a voluntary expedited development and review program administered by the FDA Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER). Designed for novel medical devices, Software as a Medical Device (SaMD), in vitro diagnostics (IVDs), and device-led combination products, the program provides intensive interactive FDA feedback and priority premarket review while preserving the statutory standards for 510(k) clearance, De Novo classification, or Premarket Approval (PMA).
What Is FDA Breakthrough Device Designation? Statutory Eligibility Criteria
Breakthrough Device Designation is not a marketing authorization in itself; rather, it is a premarket regulatory status requested via a specialized Q-Submission (Q-Sub) before the sponsor submits a final marketing application (510(k), De Novo, or PMA). It replaced the FDA’s earlier Expedited Access Pathway (EAP) and Priority Review Program (and is distinct from the drug/biologic manufacturing FDA Platform Technology Designation Program under Section 506K).
Under 21 U.S.C. § 360e-3(b) and the FDA’s final guidance (Breakthrough Devices Program: Guidance for Industry and Food and Drug Administration Staff, updated September 2023), a device must satisfy two statutory criteria to qualify:
- First Criterion (Mandatory for All Applicants): The device provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. The sponsor must demonstrate a reasonable expectation of clinical technical success (supported by bench, animal, algorithm validation, or early feasibility clinical data) and explain the mechanism of action.
- Second Criterion (Must Meet at Least One of Four Sub-Criteria):
- 2A — Breakthrough Technology: The device represents a novel technological innovation or clinical application with the potential to lead to a clinical improvement;
- 2B — No Approved or Cleared Alternatives Exist: There is currently no FDA-approved PMA, cleared 510(k), or granted De Novo device (or standard-of-care therapy) for the proposed indication;
- 2C — Offers Significant Advantages Over Existing Alternatives: Compared to currently marketed devices, the candidate device reduces hospitalizations, improves patient quality of life, enhances diagnostic sensitivity/specificity, or reduces serious procedural complications; OR
- 2D — Availability Is in the Best Interest of Patients: The device addresses an urgent public health benefit, improves patient compliance, or—under the FDA’s 2023 guidance update—reduces health and healthcare disparities in underserved populations affected by life-threatening or irreversibly debilitating conditions.
60-Day Q-Submission Review Timeline and Interactive Program Features
When a sponsor submits a Designation Request Q-Sub via the CDRH Customer Collaboration Portal (eCopy / eSTAR), the FDA follows a fixed 60-calendar-day review clock and unlocks four specialized regulatory tools upon granting designation:
| Program Mechanism | Target Timeline / Cadence | Regulatory & Clinical Development Benefit |
|---|---|---|
| Designation Q-Sub Review | Day 30 AI request; Day 60 final decision | Rapid statutory determination of Breakthrough eligibility prior to pivotal clinical trial lock or marketing submission |
| Sprint Discussions | 45-calendar-day interactive resolution cycle | Focused, high-frequency meetings with FDA review teams to reach binding agreement on a single novel testing or clinical endpoint question |
| Data Development Plan (DDP) | Negotiated iteratively across pre-IDE and pre-submission phases | Holistic lifecycle roadmap defining non-clinical and clinical evidence expectations, including premarket vs. postmarket data balance for PMAs |
| Clinical Protocol Agreement | Binding written agreement prior to pivotal study initiation | Formal FDA sign-off on pivotal Investigational Device Exemption (IDE) trial endpoints and statistical analysis plans |
| Priority Premarket Review | Front-of-queue placement for 510(k), De Novo, or PMA | Senior FDA management involvement and expedited review allocation when the final marketing application is submitted |
Premarket vs. Postmarket Evidence Balance and CMS Reimbursement (NTAP & TCET)
For Class III devices subject to Premarket Approval (PMA), Section 515B authorizes the FDA—when scientifically appropriate—to accept a greater proportion of clinical data collection in the postmarket setting (such as post-approval registries or real-world evidence studies) so long as statutory safety and effectiveness thresholds are met premarket.
Beyond FDA review speed, Breakthrough Device Designation serves as a statutory prerequisite for major Centers for Medicare & Medicaid Services (CMS) reimbursement pathways:
- CMS New Technology Add-on Payment (NTAP): Under the Medicare Hospital Inpatient Prospective Payment System (IPPS), technologies holding FDA Breakthrough Device Designation have historically qualified for streamlined eligibility pathways for NTAP, providing hospitals with supplemental inpatient payments above the standard MS-DRG rate for up to three years.
- Transitional Coverage for Emerging Technologies (TCET) and Coverage with Evidence Development (CED): Following the repeal of the proposed MCIT rule, CMS established the TCET pathway specifically for certain FDA-designated Breakthrough Devices, coordinating Evidence Development Plans (EDPs) with the Agency for Healthcare Research and Quality (AHRQ) to bridge the gap between FDA market authorization and national Medicare coverage determinations.
Frequently Asked Questions
What is FDA Breakthrough Device Designation?
FDA Breakthrough Device Designation is an expedited regulatory development and priority review program under Section 515B of the FD&C Act (21 U.S.C. § 360e-3) for medical devices and device-led combination products that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. Granted within 60 calendar days of a Q-Submission request, it provides Sprint Discussions, Data Development Plans, senior FDA management engagement, and priority review for subsequent 510(k), De Novo, or PMA submissions.
Does FDA Breakthrough Device Designation lower the standard for 510(k) clearance or PMA approval?
No. A Breakthrough-designated device must still meet the exact same statutory standards of reasonable assurance of safety and effectiveness (for PMA and De Novo) or substantial equivalence (for 510(k)), although FDA may allow flexible trial designs and balanced premarket-to-postmarket data collection under a negotiated Data Development Plan.
